Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Badanie tyragolumabu w skojarzeniu z atezolizumabem w porównaniu z placebo w skojarzeniu z atezolizumabem u pacjentów z wcześniej nieleczonym miejscowo zaawansowanym nieoperacyjnym lub przerzutowym niedrobnokomórkowym rakiem płuca wyselekcjonowanym PD-L1 (SKYSCRAPER-01)

6 listopada 2026 zaktualizowane przez: Hoffmann-La Roche

Randomizowane, podwójnie zaślepione, kontrolowane placebo badanie fazy III dotyczące tiragolumabu, przeciwciała skierowanego przeciwko tygrysowi, w skojarzeniu z atezolizumabem w porównaniu z placebo w skojarzeniu z atezolizumabem u pacjentów z wcześniej nieleczoną miejscowo zaawansowaną, nieoperacyjną lub przerzutową PD-L1-niewyselekcjonowaną -Drobnokomórkowy Rak Płuc

The purpose of the study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participants with previously untreated locally advanced, unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation. Eligible participants will be randomized in a 1:1 ratio to receive either tiragolumab plus atezolizumab or placebo plus atezolizumab.

Przegląd badań

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

620

Faza

  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • Queensland
      • Woolloongabba, Queensland, Australia, 4102
        • Princess Alexandra Hospital
    • Victoria
      • Heidelberg, Victoria, Australia, 3084
        • Austin Hospital Olivia Newton John Cancer Centre
      • Melbourne, Victoria, Australia, 3000
        • Peter Maccallum Cancer Centre
      • Linz, Austria, 4020
        • Ordensklinikum Linz Elisabethinen
      • Vienna, Austria, 1140
        • Klinik Penzing
      • Vienna, Austria, 1210
        • Krankenhaus Nord - Klinik Floridsdorf
    • Rio Grande do Sul
      • Ijuí, Rio Grande do Sul, Brazylia, 98700-000
        • Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda
    • São Paulo
      • Barretos, São Paulo, Brazylia, 14784-400
        • Hospital de Cancer de Barretos
      • Beijing, Chiny, 100142
        • Beijing Cancer Hospital
      • Changchun, Chiny, 130021
        • The First Hospital of Jilin University
      • Chengdu, Chiny, 610041
        • West China Hospital, Sichuan University
      • Chongqing, Chiny, 400030
        • Chongqing Cancer Hospital
      • Fuzhou, Chiny, 350014
        • Fujian Cancer Hospital
      • Haikou, Chiny, 570311
        • Hainan General Hospital
      • Hangzhou, Chiny, 310016
        • Sir Run Run Shaw Hospital Zhejiang University
      • Harbin, Chiny, 150081
        • Harbin Medical University Cancer Hospital
      • Jinan, Chiny, 250013
        • Jinan Central Hospital
      • Meizhou, Chiny, 514031
        • Meizhou People's Hospital
      • Nanchang, Chiny, 330200
        • The 1st Affiliated Hospital of Nanchang Unversity
      • Nantong, Chiny, 226361
        • Nantong Tumor Hospital
      • Shanghai, Chiny, 200433
        • Shanghai Pulmonary Hospital
      • Shanghai, Chiny, 200032
        • Zhongshan Hospital Fudan University
      • Shanghai, Chiny, 200120
        • Fudan University Shanghai Cancer Center
      • Wuhan, Chiny, 430022
        • Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology
      • Xi'an, Chiny, 710061
        • First Affiliated Hospital of Medical College of Xi'an Jiaotong University
      • Zhejiang, Chiny, 310022
        • Zhejiang Cancer Hospital
      • Athens, Grecja, 185 47
        • Metropolitan Hospital
      • Athens, Grecja, 104 31
        • Sotiria Hospital
      • Larissa, Grecja, 411 10
        • University Hospital of Larissa
      • Thessaloniki, Grecja, 570 01
        • Diavalkaniko Hospital
      • Madrid, Hiszpania, 28041
        • Hospital 12 de Octubre
      • Madrid, Hiszpania, 28222
        • Hospital Universitario Puerta de Hierro - Majadahonda
      • Madrid, Hiszpania, 41013
        • Hospital Universitario Virgen del Rocío
      • Málaga, Hiszpania, 29010
        • Hospital Regional Universitario de Malaga
      • Zaragoza, Hiszpania, 50009
        • Hosp Clinico Univ Lozano Blesa
    • Barcelona
      • Badalona, Barcelona, Hiszpania, 08916
        • Hospital Universitario Germans Trias i Pujol
      • 's-Hertogenbosch, Holandia, 5223 GZ
        • Jeroen Bosch Ziekenhuis
      • Ede, Holandia, 6716 RP
        • Ziekenhuis Gelderse Vallei
      • Leeuwarden, Holandia, 8934 AD
        • Frisius MC Leeuwarden
      • The Hague, Holandia, 2545 AA
        • Hagaziekenhuis, locatie Leyweg
      • Aichi, Japonia, 464-8681
        • Aichi Cancer Center
      • Chiba, Japonia, 277-8577
        • National Cancer Center Hospital East
      • Fukuoka, Japonia, 812-8582
        • Kyushu University Hospital
      • Miyagi, Japonia, 980-0873
        • Sendai Kousei Hospital
      • Niigata, Japonia, 951-8566
        • Niigata Cancer Center Hospital
      • Osaka, Japonia, 589-8511
        • Kindai University Hospital
      • Osaka, Japonia, 541-8567
        • Osaka International Cancer Institute
      • Saitama, Japonia, 362-0806
        • Saitama Cancer Center
      • Sakaishi, Japonia, 591-8555
        • NHO Kinki-Chuo Chest Medical Center
      • Shizuoka, Japonia, 411-8777
        • Shizuoka Cancer Center
      • Tokyo, Japonia, 104-0045
        • National Cancer Center Hospital
      • Tokyo, Japonia, 135-8550
        • The Cancer Institute Hospital of JFCR
      • Cheongju-si, Korea Południowa, 28644
        • Chungbuk National University Hospital
      • Gyeonggi-do, Korea Południowa, 13620
        • Seoul National University Bundang Hospital
      • Gyeonggi-do, Korea Południowa, 16499
        • Ajou University Medical Center
      • Incheon, Korea Południowa, 21565
        • Gachon University Gil Medical Center
      • Jeollanam-do, Korea Południowa, 58128
        • Chonnam National University Hwasun Hospital
      • Seoul, Korea Południowa, 03080
        • Seoul National University Hospital
      • Seoul, Korea Południowa, 05505
        • Asan Medical Center
      • Seoul, Korea Południowa, 03722
        • Severance Hospital, Yonsei University Health System
      • Seoul, Korea Południowa, 08308
        • Korea University Guro Hospital
      • Seoul, Korea Południowa, 6351
        • Samsung Medical Center
      • Seoul, Korea Południowa, 03181
        • Kangbuk Samsung Medical Center
      • Suwon, Korea Południowa, 442-723
        • St. Vincent's Hospital
    • Mexico CITY (federal District)
      • México, Mexico CITY (federal District), Meksyk, 06100
        • Cryptex Investigacion Clinica SA de CV
    • Nuevo León
      • Monterrey, Nuevo León, Meksyk, 64710
        • AVIX Investigación Clínica S.C
    • Querétaro
      • Querétaro City, Querétaro, Meksyk, 76000
        • Cuidados oncologicos
      • Frankfurt, Niemcy, 60488
        • Krankenhaus Nordwest
      • Großhansdorf, Niemcy, 22927
        • LungenClinic Großhansdorf GmbH
      • Halle, Niemcy, 06120
        • Krankenhaus Martha-Maria Halle-Doelau gGmbH
      • Immenhausen, Niemcy, 34376
        • Fachklinik für Lungenerkrankungen
      • Löwenstein, Niemcy, 74245
        • SLK Kliniken Heilbronn GmbH, Standort Fachklinik Löwenstein
      • Münster, Niemcy, 48153
        • Gemeinschaftspraxis für Hämatologie und Onkologie
      • Stuttgart, Niemcy, 70376
        • Klinik Schillerhöhe
      • Arequipa, Peru, 5154
        • Instituto Regional de Enfermedades Neoplásicas del Sur
      • Lima, Peru, 15038
        • Instituto Nacional de Enfermedades Neoplasicas
      • Lima, Peru, Lima 41
        • Clinica Internacional, Sede San Borja
      • San Isidro, Peru, Lima 27
        • Clinica Ricardo Palma
      • Gda?sk, Polska, 80-214
        • Uniwersyteckie Centrum Kliniczne
      • Olsztyn, Polska, 10-357
        • Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie
      • Poznan, Polska, 60-569
        • Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu
    • Moscow Oblast
      • Moscow, Moscow Oblast, Rosja, 143422
        • MEDSI Clinical Hospital on Pyatnitsky Highway
      • Moscow, Moscow Oblast, Rosja, 105229
        • Main Military Clinical Hospital named after N.N. Burdenko
    • Sankt-Peterburg
      • Saint Petersburg, Sankt-Peterburg, Rosja, 194291
        • Leningrad Regional Clinical Hospital
      • Saint Petersburg, Sankt-Peterburg, Rosja, 189646
        • Institute of Oncology
      • Saint Petersburg, Sankt-Peterburg, Rosja, 197089
        • St. Petersburg Med Univ
      • Saint Petersburg, Sankt-Peterburg, Rosja, 197758
        • St. Petersburg Clinical Scientific Center of special services medical assis (oncology)
      • Belgrade, Serbia, 11000
        • Clinical Center of Serbia
      • Belgrade, Serbia, 11080
        • University Hospital Medical Center Bezanijska kosa
    • Colorado
      • Denver, Colorado, Stany Zjednoczone, 80220
        • Rocky Mountain Cancer Center - Denver
    • Connecticut
      • New Haven, Connecticut, Stany Zjednoczone, 06520
        • Yale Cancer Center
    • Florida
      • St. Petersburg, Florida, Stany Zjednoczone, 33705
        • SCRI Florida Cancer Specialists North
      • Tallahassee, Florida, Stany Zjednoczone, 32308
        • SCRI Florida Cancer Specialists PAN
    • Minnesota
      • Saint Paul, Minnesota, Stany Zjednoczone, 55102
        • US oncology research at Minnesota Oncology
    • Tennessee
      • Nashville, Tennessee, Stany Zjednoczone, 37203
        • SCRI Oncology Partners
    • Virginia
      • Fairfax, Virginia, Stany Zjednoczone, 22031
        • Virginia Cancer Specialists (Fairfax) - USOR
      • Salem, Virginia, Stany Zjednoczone, 24153
        • Onc & Hem Assoc SW Virginia
      • Bern, Szwajcaria, 3010
        • Inselspital Bern
      • Lausanne, Szwajcaria, 1011
        • CHUV
      • Sankt Gallen, Szwajcaria, 9000
        • HOCH Health Ostschweiz, Kantonsspital St. Gallen
      • Bangkok, Tajlandia, 10330
        • Chulalongkorn Hospital
      • Bangkok, Tajlandia, 10400
        • Ramathibodi Hospital
      • Bangkok, Tajlandia, 10700
        • Faculty of Med. Siriraj Hosp.
      • Songkhla, Tajlandia, 90110
        • Songklanagarind Hospital
      • Guishan Dist., Tajwan, 33305
        • Chang Gung Memorial Hospital - Linkou Branch
      • Kaohsiung City, Tajwan, 83301
        • Kaohsiung Chang Gung Memorial Hospital
      • Kaohsiung City, Tajwan, 807
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • New Taipei City, Tajwan, 23561
        • Taipei Medical University ?Shuang Ho Hospital
      • Taichung, Tajwan, 407
        • Taichung Veterans General Hospital
      • Tainan, Tajwan, 704
        • National Cheng Kung Uni Hospital
      • Taipei, Tajwan, 112
        • Taipei Veterans General Hospital
      • Zhongzheng Dist., Tajwan, 10048
        • National Taiwan University Hospital
      • Adana, Turcja (Türkiye), 01120
        • Adana Baskent University Hospital
      • Ankara, Turcja (Türkiye), 06100
        • Hacettepe University Medical Faculty
      • Istanbul, Turcja (Türkiye), 34098
        • Istanbul University Cerrahpasa Faculty of Medicine
      • Izmir, Turcja (Türkiye), 35110
        • Izmir Dr. Suat Seren Gogus Hastaliklari ve Cerrahisi Egitim ve Arastirma Hastanesi
      • Kadiköy, Turcja (Türkiye), 34722
        • Goztepe Prof.Dr. Suleyman Yalcin City Hospital
      • Malatya, Turcja (Türkiye), 44280
        • Inonu University Medical Faculty of Medicine
      • Kryvyi Rih, Ukraina, 50048
        • ME Kryviy Rih Oncology Dispensary of Dnipropetrovs?k Regional Council
      • Uzhhorod, Ukraina, 88000
        • Uzhgorod Nat. University Central Municip Hosp
      • Budapest, Węgry, 1121
        • Orszagos Koranyi TBC es Pulmonologiai Intezet
      • Mátraháza, Węgry, 3233
        • Matrai Gyogyintezet
      • Szolnok, Węgry, 5004
        • Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház
    • Campania
      • Naples, Campania, Włochy, 80131
        • Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale
    • Lazio
      • Rome, Lazio, Włochy, 00151
        • Azienda Ospedaliera San Camillo Forlanini
      • Rome, Lazio, Włochy, 00168
        • Policlinico Universitario "Agostino Gemelli"
    • Lombardy
      • Milan, Lombardy, Włochy, 20141
        • Irccs Istituto Europeo di Oncologia (IEO)
      • Monza, Lombardy, Włochy, 20900
        • Asst Di Monza
      • Rozzano, Lombardy, Włochy, 20089
        • Istituto Clinico Humanitas
    • Piedmont
      • Orbassano, Piedmont, Włochy, 10043
        • Azienda Sanitaria Ospedaliera S Luigi Gonzaga
    • Umbria
      • Perugia, Umbria, Włochy, 06156
        • Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia
    • Veneto
      • Padova, Veneto, Włochy, 35128
        • IOV - Istituto Oncologico Veneto - IRCCS

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  • Histologically or cytologically documented locally advanced or recurrent NSCLC not eligible for curative surgery and/or definitive radiotherapy with or without chemoradiotherapy, or metastatic Stage IV non-squamous or squamous NSCLC
  • No prior systemic treatment for metastatic NSCLC
  • High tumor tissue PD-L1 expression
  • Measurable disease per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
  • Adequate hematologic and end-organ function
  • For participants enrolled in the extended China enrollment phase: current resident of mainland China or Taiwan and of Chinese ancestry.

Exclusion Criteria:

  • Known mutation in the EGFR gene or an ALK fusion oncogene
  • Symptomatic, untreated, or actively progressing central nervous system metastases
  • Active or history of autoimmune disease or immune deficiency
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis
  • Malignancies other than NSCLC within 5 years, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
  • Severe infection within 4 weeks prior to initiation of study treatment
  • Positive test result for human immunodeficiency virus (HIV)
  • Active hepatitis B or hepatitis C
  • Treatment with investigational therapy within 28 days prior to initiation of study treatment
  • Prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti-CTLA-4, anti-TIGIT, anti-PD-1, and anti-PD-L1 therapeutic antibodies
  • Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug elimination half-lives prior to initiation of study treatment.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Potroić

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Tiragolumab + Atezolizumab

Participants will receive atezolizumab followed by tiragolumab every 3 weeks (Q3W) on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.

Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.

Inne nazwy:
  • Tecentrik

Tiragolumab 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.

Inne nazwy:
  • MTIG7192A
Komparator placebo: Placebo + Atezolizumab

Participants will receive atezolizumab followed by placebo Q3W on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.

Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.

Inne nazwy:
  • Tecentrik

Matching Placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Global Cohort: Investigator-assessed Progression-free Survival (PFS) After Randomization According to RECIST v1.1 in the Primary Analysis Set (PAS)
Ramy czasowe: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)

PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the PAS. PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 millimeters (mm) or unequivocal progression of existing non-target lesions. Kaplan-Meier (K-M) method was used to estimate the median PFS.

From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)
China Cohort: Investigator-assessed PFS After Randomization According to RECIST v1.1 in the PAS
Ramy czasowe: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)

PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the PAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS.

From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)
Global Cohort: Overall Survival (OS) in the PAS
Ramy czasowe: From randomization to death from any cause (up to approximately 54.7 months)

OS was defined as the time from randomization to death from any cause in the PAS. K-M method was used to estimate the median OS.

From randomization to death from any cause (up to approximately 54.7 months)
China Cohort: OS in the PAS
Ramy czasowe: From randomization to death from any cause (up to approximately 49.1 months)

OS was defined as the time from randomization to death from any cause in the PAS. K-M method was used to estimate the median OS.

From randomization to death from any cause (up to approximately 49.1 months)
Global Cohort: Number of Participants With Adverse Events (AEs)
Ramy czasowe: Up to 65.1 months

An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Up to 65.1 months
China Cohort: Number of Participants With AEs
Ramy czasowe: Up to 49.3 months

An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Up to 49.3 months
Global Cohort: Number of Participants With Cytokine Release Syndrome (CRS), With Severity Determined by American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading Scale
Ramy czasowe: Up to 65.1 months

CRS was defined as supraphysiologic response following administration of immune therapy that results in activation/engagement of endogenous or infused T-cells and/or other immune effector cells. Symptoms include fever, hypotension, hypoxia, & end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades- Grade 1: fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension & hypoxia; Grade 2: fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring oxygen by positive-pressure; Grade 5: death due to CRS.

Up to 65.1 months
China Cohort: Number of Participants With CRS, With Severity Determined by ASTCT Consensus Grading Scale
Ramy czasowe: Up to 49.3 months

CRS was defined as supraphysiologic response following administration of immune therapy that results in activation/engagement of endogenous or infused T-cells and/or other immune effector cells. Symptoms include fever, hypotension, hypoxia, & end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades- Grade 1: fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension & hypoxia; Grade 2: fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring oxygen by positive-pressure; Grade 5: death due to CRS.

Up to 49.3 months

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Global Cohort: Investigator-assessed PFS According to RECIST v1.1 in the Secondary Analysis Set (SAS)
Ramy czasowe: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)

PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the SAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS.

From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)
China Cohort: Investigator-assessed PFS According to RECIST v1.1 in the SAS
Ramy czasowe: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)

PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the SAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS.

From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)
Global Cohort: OS in the SAS
Ramy czasowe: From randomization to death from any cause (up to approximately 54.7 months)

OS was defined as the time from randomization to death from any cause in the SAS. K-M method was used to estimate the median OS.

From randomization to death from any cause (up to approximately 54.7 months)
China Cohort: OS in the SAS
Ramy czasowe: From randomization to death from any cause (up to approximately 49.1 months)

OS was defined as the time from randomization to death from any cause in the SAS. K-M method was used to estimate the median OS.

From randomization to death from any cause (up to approximately 49.1 months)
Global Cohort: Investigator-assessed Confirmed Objective Response Rate (ORR) According to RECIST v1.1 in the PAS
Ramy czasowe: Up to approximately 54.6 months

Confirmed ORR was defined as the percentage of participants with a confirmed objective response (OR), characterized by either a complete response (CR) or a partial response (PR), on 2 consecutive occasions ≥ 4 weeks apart, as determined by the investigator per RECIST v1.1 in the PAS. CR was defined as the disappearance of all target and non-target lesions & normalization of tumor marker level. Additionally, any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off.

Up to approximately 54.6 months
China Cohort: Investigator-assessed Confirmed ORR According to RECIST v1.1 in the PAS
Ramy czasowe: Up to 49.3 months

Confirmed ORR was defined as the percentage of participants with a confirmed OR, characterized by either a CR or a PR, on 2 consecutive occasions ≥ 4 weeks apart, as determined by the investigator per RECIST v1.1 in the PAS. CR was defined as the disappearance of all target and non-target lesions & normalization of tumor marker level. Additionally, any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off.

Up to 49.3 months
Global Cohort: Investigator-assessed Duration of Response (DOR) According to RECIST v1.1 for Participants With Confirmed ORR in the PAS
Ramy czasowe: From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to approximately 54.6 months)

DOR for participants with confirmed ORR was defined as time from first occurrence of confirmed OR (CR or PR) to PD, as determined by the investigator per RECIST v1.1, or death from any cause, whichever occurred first in PAS. CR was defined as disappearance of all target & non-target lesions & normalization of tumor marker level. Additionally, any lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in SOD of all target lesions, taking as reference baseline SOD, in absence of CR. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference smallest SOD at prior timepoints (including baseline). Additionally, SOD must also demonstrate absolute increase of ≥5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate median DOR.

From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to approximately 54.6 months)
China Cohort: Investigator-assessed DOR According to RECIST v1.1 for Participants With Confirmed ORR in the PAS
Ramy czasowe: From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to 49.3 months)

DOR for participants with confirmed ORR was defined as time from first occurrence of confirmed OR (CR or PR) to PD, as determined by the investigator per RECIST v1.1, or death from any cause, whichever occurred first in PAS. CR was defined as disappearance of all target & non-target lesions & normalization of tumor marker level. Additionally, any lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in SOD of all target lesions, taking as reference baseline SOD, in absence of CR. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference smallest SOD at prior timepoints (including baseline). Additionally, SOD must also demonstrate absolute increase of ≥5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate median DOR.

From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to 49.3 months)
Global Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the PAS
Ramy czasowe: At Months 6 and 12

PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the PAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.

At Months 6 and 12
China Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the PAS
Ramy czasowe: At Months 6 and 12

PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the PAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.

At Months 6 and 12
Global Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the SAS
Ramy czasowe: At Months 6 and 12

PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the SAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.

At Months 6 and 12
China Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the SAS
Ramy czasowe: At Months 6 and 12

PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the SAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.

At Months 6 and 12
Global Cohort: OS Rate at 12 Months and 24 Months in the PAS
Ramy czasowe: At Months 12 and 24

OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the PAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.

At Months 12 and 24
China Cohort: OS Rate at 12 Months and 24 Months in the PAS
Ramy czasowe: At Months 12 and 24

OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the PAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.

At Months 12 and 24
Global Cohort: OS Rate at 12 Months and 24 Months in the SAS
Ramy czasowe: At Months 12 and 24

OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the SAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.

At Months 12 and 24
China Cohort: OS Rate at 12 Months and 24 Months in the SAS
Ramy czasowe: At Months 12 and 24

OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the SAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.

At Months 12 and 24
Global Cohort: Time to Confirmed Deterioration (TTCD) in Participant-reported Physical Functioning (PF), as Measured by European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) in the PAS
Ramy czasowe: Up to approximately 54.6 months

TTCD was defined as the time from randomization to first confirmed clinically meaningful deterioration (CCMD). EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), global health status (GHS)/quality-of-life (QoL), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). Functioning was scored on 4-point scale: 1=Not at all to 4=Very much. Scores were linearly transformed to range of 0-100. High score for PF scale=high/healthy level of functioning. CCMD=Clinically meaningful decrease (≥10 points) from baseline in PF score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.

Up to approximately 54.6 months
China Cohort: TTCD in Participant-reported PF, as Measured by EORTC QLQ-C30 in the PAS
Ramy czasowe: Up to approximately 49.3 months

TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). Functioning was scored on 4-point scale: 1=Not at all to 4=Very much. Scores were linearly transformed to range of 0-100. High score for PF scale=high/healthy level of functioning. CCMD=Clinically meaningful decrease (≥10 points) from baseline in PF score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.

Up to approximately 49.3 months
Global Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PAS
Ramy czasowe: Up to approximately 54.6 months

TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). GHS/QoL questions were scored on 7-point scale: 1=Very poor to 7=Excellent. Scores were linearly transformed to range of 0-100. High score for GHS/QoL scale=better health-related quality-of-life (HRQoL). CCMD=Clinically meaningful decrease (≥10 points) from baseline in GHS/QoL score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.

Up to approximately 54.6 months
China Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PAS
Ramy czasowe: Up to approximately 49.3 months

TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). GHS/QoL questions were scored on 7-point scale: 1=Very poor to 7=Excellent. Scores were linearly transformed to range of 0-100. High score for GHS/QoL scale=better HRQoL. CCMD=Clinically meaningful decrease (≥10 points) from baseline in GHS/QoL score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.

Up to approximately 49.3 months
Global Cohort: Serum Concentration of Tiragolumab at Specified Timepoints
Ramy czasowe: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-end of infusion (EOI) on Day 1 of Cycle 1; Treatment discontinuation (TD) visit (up to approximately 54.6 months) (1 Cycle=21 days)
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-end of infusion (EOI) on Day 1 of Cycle 1; Treatment discontinuation (TD) visit (up to approximately 54.6 months) (1 Cycle=21 days)
China Cohort: Serum Concentration of Tiragolumab at Specified Timepoints
Ramy czasowe: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
Global Cohort: Serum Concentration of Atezolizumab at Specified Timepoints
Ramy czasowe: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 54.6 months) (1 Cycle=21 days)
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 54.6 months) (1 Cycle=21 days)
China Cohort: Serum Concentration of Atezolizumab at Specified Timepoints
Ramy czasowe: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
Global Cohort: Number of Participants With Anti-drug Antibodies (ADAs) to Tiragolumab
Ramy czasowe: Up to approximately 54.6 months

Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following tiragolumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 titer unit (t.u.) greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

Up to approximately 54.6 months
China Cohort: Number of Participants With ADAs to Tiragolumab
Ramy czasowe: Up to approximately 49.3 months

Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following tiragolumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

Up to approximately 49.3 months
Global Cohort: Number of Participants With ADAs to Atezolizumab
Ramy czasowe: Up to approximately 54.6 months

Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following atezolizumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

Up to approximately 54.6 months
China Cohort: Number of Participants With ADAs to Atezolizumab
Ramy czasowe: Up to approximately 49.3 months

Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following atezolizumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

Up to approximately 49.3 months

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Dyrektor Studium: Clinical Trial, Hoffmann-La Roche

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

4 marca 2020

Zakończenie podstawowe (Rzeczywisty)

30 grudnia 2025

Ukończenie studiów (Rzeczywisty)

30 grudnia 2025

Daty rejestracji na studia

Pierwszy przesłany

2 marca 2020

Pierwszy przesłany, który spełnia kryteria kontroli jakości

2 marca 2020

Pierwszy wysłany (Rzeczywisty)

4 marca 2020

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

9 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

6 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • GO41717
  • 2019-002925-31 (Numer EudraCT)
  • 2019 (Grant/umowa NIH USA)
  • 2022-502482-17-00 (Ctis)

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj